INCB3344 is primarily investigated for its potential therapeutic applications in the field of immunology and oncology. It functions as a selective antagonist of the CCR2 receptor, which plays a significant role in the recruitment of monocytes and macrophages to sites of inflammation and tumor growth. By inhibiting CCR2, INCB3344 has shown promise in reducing inflammatory responses and tumor progression in preclinical studies. This makes it a candidate for treating conditions such as autoimmune diseases, chronic inflammatory disorders, and certain types of cancer. Additionally, its ability to modulate immune cell migration suggests potential applications in addressing fibrosis and other conditions driven by excessive immune cell infiltration. Research is ongoing to explore its efficacy and safety in clinical settings.